Coherus Oncology Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Coherus Oncology Inc
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Coherus Oncology Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Coherus Oncology Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Coherus Oncology Inc is CHRS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Coherus Oncology Inc has its primary listing on NASDAQ. You can trade Coherus Oncology Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Coherus Oncology Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Coherus Oncology Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Coherus Oncology Inc.